Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs) for mental health treatment, announced that CEO Michael Halstead will participate in a fireside chat at the Guggenheim Healthcare Innovation Conference in Boston. The presentation is scheduled for Monday, Nov. 9, 2026, at 3 p.m. ET. The fireside chat will be webcast live, with registration available through the conference webcast platform. A replay will be available on the Events & Presentations page of the company’s investor relations website. For more details, visit https://ibn.fm/LrRvm.
The conference appearance comes as Helus Pharma advances its pipeline of proprietary NSAs, which are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company’s NSAs aim to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. Helus Pharma is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, the company has an extensive research portfolio of investigational NSAs.
The fireside chat provides an opportunity for investors to gain insight into Helus Pharma’s clinical progress and strategic direction. With class-leading data, the company aims to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit www.helus.com.
The announcement was disseminated through InvestorWire, a specialized communications platform focused on advanced wire-grade press release syndication. InvestorWire is part of the Dynamic Brand Portfolio at IBN, which offers editorial syndication to 5,000+ outlets and social media distribution to millions of followers. These services help companies like Helus Pharma reach a wide audience of investors and journalists.
For investors, the conference participation underscores Helus Pharma’s commitment to transparency and engagement with the investment community. As the company progresses its late-stage clinical programs, updates on its NSA platform could have implications for the treatment of major depressive disorder and generalized anxiety disorder, conditions that affect millions worldwide. The fireside chat and webcast offer a chance to hear directly from leadership about the potential of NSAs to transform mental health care.
